The upcoming FDA catalyst everyone is sleeping on (Remember ABVX)

{"summary": "Bullish thesis on Medincell (Euronext: MEDCL), arguing its Teva-partnered once-monthly olanzapine LAI TEV-749 with zero PDSS cases faces an FDA decision around October 9 that could trigger an Abivax-style re-rating.", "reason": "The author provides a specific asset (Medincell), a directional thesis (long/re-rate), and a fundamental catalyst (FDA decision on TEV-749 with zero PDSS cases in Phase 3).", "ideas": [{"symbol": "MEDCL.PA", "direction": "long", "thesis": "The author argues Medincell is an under-the-radar European biotech whose Teva-partnered TEV-749, a once-monthly subcutaneous olanzapine LAI using BEPO technology, showed zero cases of Post-Injection Delirium/Sedation Syndrome in Phase 3, unlike existing LAIs carrying an FDA Black Box Warning. The claimed mechanism is a de-risked Phase 3 asset in final FDA review that US retail and institutions have not priced in, with an FDA decision expected around October 9 as the catalyst. The author cites Abivax's +500% overnight move on Phase 3 topline as the template for a similar re-rate. Main stated risk is that the thesis rests on trial guesswork versus an actual FDA decision, and the stock trades only on Euronext Paris, limiting US access.", "thesis_short": "Medincell FDA decision could trigger Abivax-style re-rate", "quote": "Medincell is setting up for a similar massive re-rate, but with an actual FDA decision on the horizon instead of just trial guesswork. Around 9th October is the date to watch!", "confidence": 0.75, "sentiment": 0.8, "timeframe": "around 9th October"}], "model": "gemini-3.1-flash-lite", "failure_count": 0, "verified": true, "extraction_model": "deepseek-flash"}